RHYTHM PHARMACEUTICALS, INC. Temporary Equity, Dividends, Adjustment
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Temporary Equity, Dividends, Adjustment of $3.87 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-03-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:TemporaryEquityDividendsAdjustment · last filed 2020-03-02
- RHYTHM PHARMACEUTICALS, INC. temporary equity, dividends, adjustment for the quarter ending 2017-12-31 was $88.00K, a 89.08% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. temporary equity, dividends, adjustment for the quarter ending 2017-09-30 was $1.41M, a 76.63% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. temporary equity, dividends, adjustment for the quarter ending 2017-06-30 was $1.21M.
- RHYTHM PHARMACEUTICALS, INC. temporary equity, dividends, adjustment for the quarter ending 2017-03-31 was $1.17M.
- RHYTHM PHARMACEUTICALS, INC. temporary equity, dividends, adjustment for fiscal 2017 was $3.87M, a 20.96% increase from fiscal 2016.
- RHYTHM PHARMACEUTICALS, INC. temporary equity, dividends, adjustment for fiscal 2016 was $3.20M.
| Period end | Temporary Equity, Dividends, Adjustment 3 month | Temporary Equity, Dividends, Adjustment 6 month | Temporary Equity, Dividends, Adjustment 9 month | Temporary Equity, Dividends, Adjustment 12 month |
|---|---|---|---|---|
| 2017-12-31 | $88.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $1.50M derived: sum of 2 quarters · filed 2020-03-02 | $2.71M derived: sum of 3 quarters · filed 2020-03-02 | $3.87M 10-K · filed 2020-03-02 |
| 2017-09-30 | $1.41M 10-Q · filed 2018-11-09 | $2.62M derived: sum of 2 quarters · filed 2018-11-09 | $3.79M 10-Q · filed 2018-11-09 | $4.59M derived: sum of 4 quarters · filed 2019-03-08 |
| 2017-06-30 | $1.21M 10-Q · filed 2018-08-08 | $2.37M 10-Q · filed 2018-08-08 | $3.18M derived: sum of 3 quarters · filed 2019-03-08 | $3.98M derived: sum of 4 quarters · filed 2019-03-08 |
| 2017-03-31 | $1.17M 10-Q · filed 2018-05-14 | $1.97M derived: sum of 2 quarters · filed 2019-03-08 | $2.77M derived: sum of 3 quarters · filed 2019-03-08 | |
| 2016-12-31 | $806.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $1.61M derived: sum of 2 quarters · filed 2019-03-08 | $3.20M 10-K · filed 2019-03-08 | |
| 2016-09-30 | $800.00K 10-Q · filed 2017-11-14 | $2.40M 10-Q · filed 2017-11-14 | ||
| 2015-12-31 | $927.00K 8-K · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |